Ensign Peak Advisors Inc Has $11.16 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Ensign Peak Advisors Inc cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 10.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 335,000 shares of the biotechnology company's stock after selling 40,616 shares during the period. Ensign Peak Advisors Inc owned 0.12% of Exelixis worth $11,156,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Blue Trust Inc. increased its stake in shares of Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock worth $476,000 after purchasing an additional 8,208 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Exelixis during the 4th quarter worth about $17,046,000. Allspring Global Investments Holdings LLC increased its stake in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after purchasing an additional 704,786 shares during the last quarter. Inspire Investing LLC boosted its holdings in shares of Exelixis by 25.0% during the 4th quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company's stock worth $1,221,000 after buying an additional 7,331 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in shares of Exelixis by 4.6% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 505,289 shares of the biotechnology company's stock worth $16,826,000 after buying an additional 22,225 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on EXEL shares. Piper Sandler lifted their target price on shares of Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Guggenheim reaffirmed a "buy" rating and set a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Stifel Nicolaus lifted their target price on shares of Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Exelixis in a report on Thursday, March 27th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $38.76.

Insider Activity

In related news, EVP Patrick J. Haley sold 52,636 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This represents a 14.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the transaction, the chief financial officer now owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. This represents a 3.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 520,942 shares of company stock worth $22,930,002. 2.82% of the stock is currently owned by corporate insiders.

Exelixis Stock Down 1.9%

Shares of NASDAQ:EXEL traded down $0.86 during midday trading on Friday, hitting $45.40. The stock had a trading volume of 5,538,335 shares, compared to its average volume of 2,270,083. The company's 50-day moving average price is $37.23 and its 200-day moving average price is $35.80. The company has a market capitalization of $12.51 billion, a P/E ratio of 25.65, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $48.85.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.